Chouw Angliana, Milanda Tiana, Sartika Cynthia Retna, Kirana Marsya Nilam, Halim Danny, Faried Ahmad
Post-Doctoral Program, Faculty of Pharmacy, Universitas Padjajaran, Jalan Raya Bandung Sumedang Km. 21, Jatinangor, West Java Indonesia.
Prodia StemCell Indonesia, Jalan Kramat 7 No 11, Jakarta Pusat, DKI Jakarta Indonesia.
Regen Eng Transl Med. 2022;8(1):43-54. doi: 10.1007/s40883-021-00202-5. Epub 2021 Mar 10.
The COVID-19 disease, which is caused by the novel coronavirus, SARS-CoV-2, has affected the world by increasing the mortality rate in 2020. Currently, there is no definite treatment for COVID-19 patients. Several clinical trials have been proposed to overcome this disease and many are still under investigation. In this review, we will be focusing on the potency of mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. Fever, cough, headache, dizziness, and fatigue are the common clinical manifestations in COVID-19 patients. In mild and severe cases, cytokines are released hyper-actively which causes a cytokine storm leading to acute respiratory distress syndrome (ARDS). In order to maintain the lung microenvironment in COVID-19 patients, MSCs are used as cell-based therapy approaches as they can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote endogenous repair. Besides, MSCs have shown minimal expression of ACE2 or TMPRSS2, and hence, MSCs are free from SARS-CoV-2 infection. Numerous clinical studies have started worldwide and demonstrated that MSCs have great potential for ARDS treatment in COVID-19 patients. Preliminary data have shown that MSCs and MSC-derived secretome appear to be promising in the treatment of COVID-19.
The COVID-19 disease is an infection disease which affects the world in 2020. Currently, there is no definite treatment for COVID-19 patients. However, several clinical trials have been proposed to overcome this disease and one of them is using mesenchymal stem cells (MSCs) and MSC-derived secretome for treating COVID-19 patients. During the infection, cytokines are released hyper-actively which causes a cytokine storm. MSCs play an important role in maintaining the lung microenvironment in COVID-19 patients. They can act as cell managers which accelerate the immune system to prevent the cytokine storm and promote the endogenous repair. Therefore, it is important to explore the clinical trial in the world for treating the COVID-19 disease using MSCs and MSC-derived secretome.
由新型冠状病毒SARS-CoV-2引起的2019冠状病毒病在2020年通过提高死亡率影响了全球。目前，对于2019冠状病毒病患者尚无确切的治疗方法。已经提出了多项临床试验来攻克这种疾病，许多试验仍在研究中。在本综述中，我们将聚焦于间充质干细胞（MSCs）及其分泌组治疗2019冠状病毒病患者的潜力。发热、咳嗽、头痛、头晕和疲劳是2019冠状病毒病患者的常见临床表现。在轻症和重症病例中，细胞因子过度释放，引发细胞因子风暴，导致急性呼吸窘迫综合征（ARDS）。为了维持2019冠状病毒病患者的肺微环境，MSCs被用作基于细胞的治疗方法，因为它们可以充当细胞管理者，加速免疫系统以预防细胞因子风暴并促进内源性修复。此外，MSCs显示出极低的血管紧张素转换酶2（ACE2）或跨膜丝氨酸蛋白酶2（TMPRSS2）表达，因此，MSCs不会感染SARS-CoV-2。全球范围内已经开展了许多临床研究，并证明MSCs在治疗2019冠状病毒病患者的ARDS方面具有巨大潜力。初步数据表明，MSCs及其分泌组在治疗2019冠状病毒病方面似乎很有前景。
2019冠状病毒病是一种在2020年影响全球的传染病。目前，对于2019冠状病毒病患者尚无确切的治疗方法。然而，已经提出了多项临床试验来攻克这种疾病，其中之一是使用间充质干细胞（MSCs）及其分泌组治疗2019冠状病毒病患者。在感染期间，细胞因子过度释放，引发细胞因子风暴。MSCs在维持2019冠状病毒病患者的肺微环境中发挥着重要作用。它们可以充当细胞管理者，加速免疫系统以预防细胞因子风暴并促进内源性修复。因此，在全球范围内探索使用MSCs及其分泌组治疗2019冠状病毒病的临床试验非常重要。
